Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Amortization of Deferred Charges (2019 - 2025)

Tg Therapeutics (TGTX) has 8 years of Amortization of Deferred Charges data on record, last reported at $288000.0 in Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges fell 4.95% year-over-year to $288000.0; the TTM value through Dec 2025 reached $1.2 million, down 39.85%, while the annual FY2025 figure was $1.2 million, 39.85% down from the prior year.
  • Amortization of Deferred Charges reached $288000.0 in Q4 2025 per TGTX's latest filing, down from $304000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $700000.0 in Q3 2021 and bottomed at $231000.0 in Q1 2021.
  • Average Amortization of Deferred Charges over 5 years is $448300.0, with a median of $461000.0 recorded in 2022.
  • Peak YoY movement for Amortization of Deferred Charges: surged 203.03% in 2021, then plummeted 52.58% in 2024.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $386000.0 in 2021, then rose by 19.43% to $461000.0 in 2022, then surged by 38.61% to $639000.0 in 2023, then tumbled by 52.58% to $303000.0 in 2024, then dropped by 4.95% to $288000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $288000.0 in Q4 2025, $304000.0 in Q3 2025, and $304000.0 in Q2 2025.